Crossmark

Structure-based discovery of opioid analgesics with reduced side effects

Crossref DOI link: https://doi.org/10.1038/nature19112

Published Online: 2016-08-17

Published Print: 2016-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Manglik, Aashish

Lin, Henry

Aryal, Dipendra K.

McCorvy, John D.

Dengler, Daniela

Corder, Gregory

Levit, Anat

Kling, Ralf C.

Bernat, Viachaslau

Hübner, Harald

Huang, Xi-Ping

Sassano, Maria F.

Giguère, Patrick M.

Löber, Stefan

Da Duan,

Scherrer, Grégory

Kobilka, Brian K.

Gmeiner, Peter

Roth, Bryan L.

Shoichet, Brian K.
License Information

Text and Data Mining valid from 2016-08-17
More Information

Article History

Received: 25 November 2015

Accepted: 14 July 2016

First Online: 17 August 2016

Competing interests

: A.M., H.L., P.G., D.D., B.K.K., B.L.R. and B.K.S. have filed a provisional patent on PZM21 and related molecules. A.M., P.G., B.K.K., B.L.R. and B.K.S. are consultants and co-founders of Epiodyne, a company seeking to develop novel analgesics.